tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Valneva announces U.S. FDA’s decision to suspend license of IXCHIQ
PremiumThe FlyValneva announces U.S. FDA’s decision to suspend license of IXCHIQ
2M ago
Valneva SE (ADR) trading halted, news pending
Premium
The Fly
Valneva SE (ADR) trading halted, news pending
2M ago
Valneva’s Promising Future: Buy Rating Backed by VLA15 Vaccine and Robust Portfolio
Premium
Ratings
Valneva’s Promising Future: Buy Rating Backed by VLA15 Vaccine and Robust Portfolio
2M ago
Valneva drops 2% to $6.05 after UK restricts vaccine use
PremiumThe FlyValneva drops 2% to $6.05 after UK restricts vaccine use
4M ago
Valneva says IXCHIQ ‘well tolerated’ by children ages 1-11 years
Premium
The Fly
Valneva says IXCHIQ ‘well tolerated’ by children ages 1-11 years
5M ago
Valneva’s Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Valneva’s Earnings Call: Growth Amid Challenges
5M ago
Positive Outlook for Valneva Driven by Promising Vaccine Pipeline and Strategic Developments
PremiumRatingsPositive Outlook for Valneva Driven by Promising Vaccine Pipeline and Strategic Developments
6M ago
Valneva granted EC marketing authorization for Ixchiq vaccine
Premium
The Fly
Valneva granted EC marketing authorization for Ixchiq vaccine
7M ago
Valneva’s Strategic Advancements and Promising Projections Drive Buy Rating with $17 Target
Premium
Ratings
Valneva’s Strategic Advancements and Promising Projections Drive Buy Rating with $17 Target
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100